Our investment case
Five compelling reasons to invest in Imperial Brands
Five compelling reasons to invest in Imperial Brands
As the smallest of the global players in the tobacco and nicotine industry, we play to our natural strengths as a challenger business. This means identifying opportunities overlooked by competitors and executing with speed and agility, supported by strong capabilities and culture.
Our challenger approach has enabled us to revitalise our tobacco business. Selective investments in brands and sales execution in priority markets have driven growing aggregate market share, alongside strong pricing, and improving profitability and cash generation. In the majority of our larger markets, tobacco remains affordable and we see opportunities to create even greater value in the future.
We are committed to building a growing and profitable next generation product business through disciplined prioritisation and investment. We innovate working in collaboration with partners and enter markets where there is proven demand and we have established routes to market.
This way of working has enabled us to build strong offerings in all categories since 2020.
As we build scale and become even more targeted in our consumer propositions, we see opportunities to continue to increase gross margins and grow NGP at an annual double-digit pace.
We are five years into a highly structured change programme which has delivered enhanced consumer capabilities, a culture of high performance, and improving tech and data.
The full benefits of these investments will emerge during the next five-year strategic period as we further improve insights, innovation and marketing, continue to develop our people and ways of working, and complete long-term digital programmes.
We carefully prioritise how we use your capital.
First, we invest in our strategy. Our strategy is largely organic, and our capital expenditure needs are relatively light.
Second, we maintain leverage at the lower end of 2.0-2.5 times adjusted net debt/EBITDA, ensuring our investment grade credit rating.
Third we have a progressive dividend policy growing payments annually, considering the underlying business performance.
Finally, we return surplus cash to shareholders through ongoing buybacks.
Our business model is aligned to a long-term consumer trend towards potentially less harmful smoke-free nicotine products. All our products are for adults who already smoke or consume nicotine and we are committed to playing a material role in reducing the harm caused by tobacco.
We also have clear plans to make material progress across a full range of environmental and social priorities, including by becoming fully carbon neutral by 2040.
Our well embedded purpose – to forge a healthier future for moments of relaxation and pleasure – continues to guide our business.
Improving tobacco and NGP net revenue trajectory, with a compound annual growth rate of 1% to 2%.
Enhancing profitability through operational leverage, better geographic mix from continued stabilisation of priority market shares, reduced losses from our investment in NGP and restructuring cost savings driving a mid single-digit compound annual growth rate for Group adjusted operating profit.
The business is highly cash generative with low capital intensity, a working capital focus and disciplined capital expenditure producing adjusted operating cash conversion of typically 90% to 100%.
We have a clear capital allocation framework alongside our strategy:
1. Invest in strategy
Since our strategy is largely organic and we work with innovation partners, our capital expenditure needs are relatively light. Any M&A is likely to be small.
2. Maintain leverage
We are committed to an investment grade credit rating and will maintain our leverage at the lower end of the range 2.0-2.5 times adjusted net debt/EBITDA.
3. Progressive dividend growth
We have committed to grow our dividend every year, taking into account the underlying business performance.
4. Return surplus capital to shareholders
We have an ongoing share buyback programme, with £1.25 billion committed in FY25.